What the FDA peptide compounding policy would and would not do
A notice is sitting at the FDA waiting to be published. Here is what is known, what is guessed, and what would change for a person holding a vial.
On 14 October 2026 the FDA sent a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House regulatory review office. The entry on reginfo.gov, filed as RIN 0910-ZD94, calls it a notice rather than a rule. Review ended on 27 October. Secondary reports say it was marked "consistent with change", the label for a document the White House cleared after edits. As of 28 October 2026 the FDA has not published it, and its text has not been seen outside the government.
Where this came from
In the United States a pharmacy may compound a drug from a bulk substance only if that substance is an approved drug ingredient, has a monograph, or appears on the FDA's 503A bulks list. None of the popular grey-market peptides qualifies, which is why they are sold "for research use only" and why no pharmacy can lawfully fill a prescription for them.
In 2023 the FDA placed a group of these peptides in Category 2, the list of nominated substances with significant safety concerns. In April 2026 it removed twelve of them from that category and scheduled hearings. On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee reviewed seven and recommended six for the bulks list, over the objection of the agency's own reviewers, who had advised against all seven. The six, with our grade for each: BPC-157 (C), KPV (C), TB-500 (C), MOTS-c (C), Epitalon (C), Semax (B). The seventh, DSIP, was not recommended. BPC-157, KPV and TB-500 each passed eight votes to six with one abstention. MOTS-c passed seven to five.
A committee vote changes nothing on its own. Adding a substance to the bulks list requires a proposed rule, a comment period and a final rule, a process the FDA has historically taken a year or longer to finish. The interim policy is the agency's answer to that gap.
What it would most likely do
Nobody outside the agency has read it, so this section rests on the title, the "notice" classification, and reporting from the Associated Press and trade lawyers. The consistent account is enforcement discretion: the FDA would state that it does not intend to act against state-licensed pharmacies that compound certain named peptides for individual patients on a prescription, provided they meet conditions the notice sets out. Those conditions are expected to cover where the raw peptide comes from, how it is tested, and what the pharmacy reports back.
Only BPC-157 has been named as covered, by two unnamed sources speaking to the Associated Press. Whether the other five from the July vote are included is not known.
What it would not do
It would not approve any peptide. Approval requires a company to run trials and submit an application, and none of the six has one. The grade on each page would not move, because the grade measures what has been tested, and a policy notice tests nothing.
It would not add anything to the 503A bulks list. That still needs rulemaking. A notice of enforcement discretion can also be narrowed or withdrawn by the FDA without a comment period, which a rule cannot.
It would not change the position of online vendors selling vials marked for research use. Those sales are outside the pharmacy channel the notice addresses. It would not bind state pharmacy boards, several of which have their own restrictions on compounding peptides, and it would not cover outsourcing facilities under section 503B unless the text says so.
What to watch for when it lands
Four things in the published text will decide what it means in practice: the list of peptides, whether a prescription from a physician who has examined the patient is required, the sourcing and testing conditions, and the end date, since an interim policy is by definition temporary. The FDA's own scientists told the committee in July that the published human studies on these compounds are too small and too short to establish safety or effectiveness, so the notice may also carry labelling or reporting requirements that reflect that.
The upcoming decisions page carries the entry and will show the publication date once there is one. Each of the six pages above will be updated the day the text appears. If you want a note when that happens, add the compound to your watchlist.
Published 2026-10-28. Sources: reginfo.gov RIN 0910-ZD94; FDA Pharmacy Compounding Advisory Committee, 23 and 24 July 2026; Associated Press, October 2026. This page describes regulation and is not legal or medical advice.